Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 8/20 | 0.56 |
| ▸ | EGFR | P00533 | 4/20 | 0.53 |
| ▸ | JAK3 | P52333 | 7/20 | 0.52 |
| ▸ | JAK2 | O60674 | 4/20 | 0.52 |
| ▸ | JAK1 | P23458 | 3/20 | 0.52 |
| ▸ | TYK2 | P29597 | 2/20 | 0.52 |
| ▸ | TTK | P33981 | 1/20 | 0.52 |
| ▸ | FLT3 | P36888 | 2/20 | 0.51 |
| ▸ | BLK | P51451 | 2/20 | 0.51 |
| ▸ | SYK | P43405 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30931315 | 0.93 | BTK (0.58) | BTKEGFRJAK3JAK2JAK1 | |
| SCHEMBL27240931 | 0.93 | BTK (0.58) | BTKEGFRJAK3JAK2JAK1 | |
| SCHEMBL29929709 | 0.91 | BTK (0.62) | BTKEGFRJAK3JAK2JAK1 | |
| SCHEMBL26980738 | 0.91 | BTK (0.62) | BTKEGFRJAK3JAK2JAK1 | |
| SCHEMBL27240764 | 0.89 | BTK (0.54) | BTKEGFRJAK3JAK2JAK1 | |
| SCHEMBL27240879 | 0.86 | JAK3 (0.56) | BTKEGFRJAK3JAK2JAK1 | |
| SCHEMBL27240828 | 0.85 | BTK (0.65) | BTKEGFRJAK3JAK2JAK1 | |
| SCHEMBL29929091 | 0.85 | JAK2 (0.60) | BTKEGFRJAK3JAK2JAK1 | |
| SCHEMBL26977501 | 0.85 | JAK2 (0.60) | BTKEGFRJAK3JAK2JAK1 | |
| SCHEMBL27240824 | 0.85 | JAK3 (0.51) | BTKEGFRJAK3JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240190849-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF THEIR USE | TYRA BIOSCIENCES, INC. | 2024-06-13 | — | — | US | claimed |
| US-20240190849-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF THEIR USE | TYRA BIOSCIENCES, INC. | 2024-06-13 | — | — | US | disclosed |
| EP-4297873-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF THEIR USE | Tyra Biosciences, Inc. (US) | 2024-01-03 | — | — | EP | disclosed |
| CN-117136184-A | Aminopyrimidine compounds and methods of use thereof | 泰拉生物科学公司 | 2023-11-28 | — | — | CN | disclosed |
| WO-2022182972-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF THEIR USE | TYRA BIOSCIENCES, INC. (US) | 2022-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240190849-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF THEIR USE | DPYD, TYMP, TYMS | BTK 2153/4885EGFR 1313/4885JAK3 1800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.